Sen. Bernie Sanders (I-Vt.) has once again criticized Novo Nordisk A/S (NYSE:NVO) for the high price of its diabetes drug, Ozempic, in the United States. What Happened: On Sunday, Sanders took to X to express his concerns about the pricing disparity of Ozempic in the U.S. compared to other countries. He highlighted that generic drug companies can sell Ozempic at a profit for less than $100, while Americans are paying almost $1,000 a month for the drug. Sanders attributed this price discrepancy to corporate greed and called on Novo Nordisk to reduce the price of Ozempic. He said, “So why does y…
